Sharlene M. Day, MD

faculty photo
Presidential Associate Professor
Department: Medicine
Graduate Group Affiliations

Contact information
3400 Civic Center Blvd
Smilow 11-102
Philadelphia, PA 19125
Office: 2155734650
Education:
BS (Biology)
Massachusetts Institute of Technology, 1991.
M.D. (Medicine)
New York University School of Medicine, 1995.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

My clinical expertise is in inherited or genetic heart diseases, including hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, left ventricular noncompaction cardiomyopathy, long QT syndrome and other channelopathies.

Description of Research Expertise

My research program primarily focuses on hypertrophic cardiomyopathy (HCM), the most common genetic cardiovascular disease of Mendelian inheritance. Our research program integrates basic, translational and clinical science. We have a strong interest in learning how genetic and non-genetic factors (particularly exercise) influence the cardiovascular phenotype and clinical outcomes in patients. We have pursued these questions through a large multicenter registry and several clinical trials. To better understand the molecular pathophysiology of HCM, we leverage a variety of resources and model systems, including human heart tissue from genotyped HCM patients, exogenous expression of sarcomere gene mutations in primary cardiac myocytes, and a series of human inducible pluripotent stem cell-derived cardiac myocyte (hiPSC-CM) models of hypertrophic cardiomyopathy in isogenic lines through genome-editing, as well as patient-derived iPSC lines. Our early work focused on defining gene and allele-specific sarcomere gene expression and specific alterations in calcium homeostasis in human HCM. In recent years, we have primarily focused on myosin binding protein C (MYBPC3), the gene that harbors the largest number of mutations causal for hypertrophic cardiomyopathy. In human myocardium from patients with MYBPC3 mutations, we have defined loss-of-function, or haploinsufficiency of MYBPC3, as the primary pathophysiology. Our lab has identified a critical regulator, the HSP70 family of molecular chaperones, in the turnover of MYBPC3 and are pursuing this pathway as a possible therapeutic target. We have recently completed a small molecule screen of ~2500 compounds in patient-derived iPSC-CMs and have identified a number of other putative candidates that could restore haploinsufficiency of MYBPC3 caused by mutations in this gene.

Selected Publications

Walsh R, Mazzarotto F, Whiffin N, Buchan R, Midwinter W, Wilk A, Li N, Felkin L, Ingold N, Govind R, Ahm,ad M, Mazaika E, Allouba M, Zhang X, de Marvao A, Day SM, Ashley E, Colan SD, Michels M, Pereira AC, Jacoby D, Ho CY, Thomson KL, Watkins H, Barton PJR, Olivotto, I, Cook SA, Ware JS.: Quantitative Approaches to Variant Classification Increase the Yield and Precision of Genetic Testing for Mendelian Diseases: The Case for Hypertrophic Cardiomyopathy. Genome Medicine 11(1): 5, Jan 2019.

Garratt M, Leander D, Pifer K, Herrera J, Day SM, Fiehn O, Brooks S, Miller RA. : 17-alpha Estradiol Ameliorates Age-Associated Sarcopenia and Improves Late Life Physical Function in Male Mice But Not in Females or Castrated Males Aging Cell 18(2): e12920, April 2019.

Day SM: Nonobstructive Hypertrophic Cardiomyopathy: The High Hanging Fruit. JAMA Cardiol 4(3): 235-236, Mar 2019

Vigneault DM, Yang E, Jensen PJ, Tee MW, Farhad H, Chu L, Noble JA, Day SM, Colan SD, Russell MW, Towbin J, Sherrid MV, Canter CE, Shi L, Ho CY, Bluemke DA: Left Ventricular Strain Is Abnormal in Preclinical and Overt Hypertrophic Cardiomyopathy: Cardiac MR Feature Tracking. Radiology 290(3): 640-48, Mar 2019.

Smith ED, Tome J, Mcgrath R, Kumar S, Concannon M, Day SM, Saberi S, Helms AS: Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death. Int J Cardiol 274: 226-231, Jan 2019.

O'Leary TS, Snyder J, Sadayappan S, Day SM, Previs MJ: MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy. J Mol Cell Cardiol 127: 165-173, Dec 2018.

Glazier AA, Thompson A, Day SM: Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy. Pflugers Arch Page: 1-13, Nov 2018.

Ho CY, Day, SM, Ashley EA, Michels M, Pereira A, Jacoby D, Fox J, Caleshu C, Cirino AL, Ware J, Helms AS, Colan SD, Signorovich J, Green E, Olivotto I: Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 138(14): 1387-98, Oct 2 2018 Notes:

LLee SP, Ashley EA, Homburger J, Caleshu C, Green EM, Jacoby D, Colan SD, Arteaga-Fernández E, Day SM, Girolami F, Olivotto I, Michels M, Ho CY, Perez MV, SHaRe Investigators: Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. Circ Heart Fail 11(9): e005191, Sep 2018.

Glazier AA, Hafeez N, Mellacheruvu D, Basrur V, Nesvizhskii AI, Lee LM, Shao H, Tang V, Yob JM, Gestwicki JE, Helms AS, Day SM: HSC70 is a chaperone for wild-type and mutant cardiac myosin binding protein C. JCI Insight 3(11): pii: 99319, Jun 2018.

Tang VT, Arscott P, Helms AS, Day SM: Whole-Exome Sequencing Reveals GATA4 and PTEN Mutations as a Potential Digenic Cause of Left Ventricular Noncompaction. Circ Genom Precis Med 11(1): e001966, Jan 2018.

Limongelli G, Bossone E, Elliott PM, Day SM: On the Road from Gene to Therapy in Inherited Cardiomyopathies. Heart Fail Clin 14(2): xi-xv, Apr 2018.

Saberi Sara, Day Sharlene M: Exercise and Hypertrophic Cardiomyopathy: Time for a Change of Heart. Circulation 137(5): 419-421, Jan 2018.

Saberi S, Day SM: Vigorous exercise in hypertrophic cardiomyopathy: Benefits may outweigh the risks. Int J Cardiol 250: 229-230, Jan 2018.

Furqan A, Arscott P, Girolami F, Cirino AL, Michels M, Day SM, Olivotto I, Ho CY, Ashley E, Green EM, Caleshu C, SHaRe Consortium: Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. Circ Cardiovasc Genet 10(5): pii: e001700, Oct 2017.

Cirino AL, Harris S, Lakdawala NK, Michels M, Olivotto I, Day SM, Abrams DJ, Charron P, Caleshu C, Semsarian C, Ingles J, Rakowski H, Judge DP1, Ho CY: Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. JAMA Cardiol 2(10): 1153-1160, Oct 2017.

Saberi S, Wheeler M, Bragg-Gresham J, Hornsby W, Agarwal PP, Attili A, Concannon M, Dries AM, Shmargad Y, Salisbury H, Kumar S, Herrera JJ, Myers J, Helms AS, Ashley EA, Day SM: Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA 317(13): 1349-1357, Apr 2017.

Ho CY, Day SM, Colan SD, Russell MW, Towbin JA, Sherrid MV, Canter CE, Jefferies JL, Murphy AM, Cirino AL, Abraham TP, Taylor M, Mestroni L, Bluemke DA, Jarolim P, Shi L, Sleeper LA, Seidman CE, Orav EJ; HCMNet Investigators: The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study. JAMA Cardiol 2(4): 419-428, Apr 2017.

Helms AS, Alvarado FJ, Yob J, Tang VT, Pagani F, Russell MW, Valdivia HH, Day SM.: Genotype-Dependent and -Independent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy. Circulation 134(22): 1738-1748, Nov 2016.

Monteiro da Rocha A1, Guerrero-Serna G2, Helms A2, Luzod C2, Mironov S2, Russell M3, Jalife J2, Day SM2, Smith GD4, Herron TJ5.: Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. J Mol Cell Cardiol 99: 197-206, Oct 2016.

Homburger JR, Green EM, Caleshu C, Sunitha MS, Taylor RE, Ruppel KM, Metpally RPR, Colan SD, Michels M, Day SM, Olivotto I, Bustamante CD, Dewey FE, Ho Y, Spudich JA, Ashley EA: Multidimensional structure-function relationships in human ╬▓-cardiac myosin from population-scale genetic variation. PNAS 113(24): 6701-6, Jun 2016.

Helms AS, Day SM: Hypertrophic cardiomyopathy: single gene disease or complex trait? Eur Heart J 37(23): 1823-5, Jun 2016.

Helms AS, Davis FM, Coleman D, Bartolone SN, Glazier AA, Pagani F, Yob JM, Sadayappan S, Pedersen E, Lyons R, Westfall MV, Jones R, Russell MW1, Day SM: Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy. Circ Cardiovasc Genet 7(4): 434-43, Aug 2014.

Reineck E, Rolston B, Bragg-Gresham JL, Salberg L, Baty L, Kumar S, Wheeler MT, Ashley E, Saberi S, Day SM: Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy. Am J Cardiol 111(7): 1034-9, Apr 2013.

Ko C, Arscott P, Saberi S, Concannon M, Day SM, Yashar BM, Helms AS: Genetic Testing Impacts the Utility of Prospective Familial Screening in Hypertrophic Cardiomyopathy Through Identification of a Non-Familial Subgroup. Genetics in Medicine 20(1): 69-75, 2018.

Ahmad F, McNally EM, Ackerman MJ, Baty LC, Day SM, Kullo IJ, Madueme PC, Maron MS, Martinez MW, Phetteplace JE, Salberg L, Taylor MR: Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting the Standards. Circ Genom Precis Med 12(6): 286-305, June 2019.

back to top
Last updated: 09/29/2021
The Trustees of the University of Pennsylvania